These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 28778132)

  • 1. Olaratumab: A Novel Platelet-Derived Growth Factor Receptor α-Inhibitor for Advanced Soft Tissue Sarcoma.
    Andrick BJ; Gandhi A
    Ann Pharmacother; 2017 Dec; 51(12):1090-1098. PubMed ID: 28778132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
    Tap WD; Jones RL; Van Tine BA; Chmielowski B; Elias AD; Adkins D; Agulnik M; Cooney MM; Livingston MB; Pennock G; Hameed MR; Shah GD; Qin A; Shahir A; Cronier DM; Ilaria R; Conti I; Cosaert J; Schwartz GK
    Lancet; 2016 Jul; 388(10043):488-97. PubMed ID: 27291997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olaratumab for advanced soft tissue sarcoma.
    Tobias A; O'brien MP; Agulnik M
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):699-705. PubMed ID: 28447475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olaratumab for the treatment of advanced soft tissue sarcoma.
    Okuno SH; Maran A; Robinson SI
    Expert Rev Anticancer Ther; 2017 Oct; 17(10):883-887. PubMed ID: 28862476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olaratumab in the management of advanced soft tissue sarcoma.
    Zobniw CM; Trinh VA; Posey K; Somaiah N
    J Oncol Pharm Pract; 2019 Mar; 25(2):442-448. PubMed ID: 30032714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma.
    Villalobos VM; Mo G; Agulnik M; Pollack SM; Rushing DA; Singh A; Van Tine BA; McNaughton R; Decker RL; Zhang W; Shahir A; Cronier DM
    Cancer Med; 2020 Feb; 9(3):882-893. PubMed ID: 31821732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
    McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
    BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial.
    Tap WD; Wagner AJ; Schöffski P; Martin-Broto J; Krarup-Hansen A; Ganjoo KN; Yen CC; Abdul Razak AR; Spira A; Kawai A; Le Cesne A; Van Tine BA; Naito Y; Park SH; Fedenko A; Pápai Z; Soldatenkova V; Shahir A; Mo G; Wright J; Jones RL;
    JAMA; 2020 Apr; 323(13):1266-1276. PubMed ID: 32259228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts.
    Cornillie J; Wozniak A; Van Renterghem B; Van Winkel N; Wellens J; Gebreyohannes YK; Debiec-Rychter M; Sciot R; Hompes D; Schöffski P
    BMC Cancer; 2019 Jul; 19(1):724. PubMed ID: 31331295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olaratumab for the treatment of soft tissue sarcoma.
    Deshpande HA; Cecchini M; Ni Choileain S; Jones R
    Drugs Today (Barc); 2017 Apr; 53(4):247-255. PubMed ID: 28492292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α.
    Lowery CD; Blosser W; Dowless M; Knoche S; Stephens J; Li H; Surguladze D; Loizos N; Luffer-Atlas D; Oakley GJ; Guo Q; Iyer S; Rubin BP; Stancato L
    Clin Cancer Res; 2018 Feb; 24(4):847-857. PubMed ID: 29191969
    [No Abstract]   [Full Text] [Related]  

  • 12. Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy.
    Davis EJ; Chugh R
    Drug Des Devel Ther; 2017; 11():3579-3587. PubMed ID: 29263653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas.
    Vincenzi B; Badalamenti G; Napolitano A; Spalato Ceruso M; Pantano F; Grignani G; Russo A; Santini D; Aglietta M; Tonini G
    Crit Rev Oncol Hematol; 2017 Oct; 118():1-6. PubMed ID: 28917265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma.
    Yonemori K; Kodaira M; Satoh T; Kudo T; Takahashi S; Nakano K; Ando Y; Shimokata T; Mori J; Inoue K; Oakley GJ; Sakaguchi S; Tamura K
    Cancer Sci; 2018 Dec; 109(12):3962-3970. PubMed ID: 30353601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma.
    Martín-Broto J; Pousa AL; Brohl AS; Van Tine BA; Powers B; Stacchiotti S; Blay JY; Hu JS; Oakley GJ; Wang H; Szpurka AM; Levy DE; Mo G; Ceccarelli M; Jones RL
    Mol Cancer Ther; 2021 Jan; 20(1):132-141. PubMed ID: 33177152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olaratumab in soft tissue sarcoma - Current status and future perspectives.
    Antoniou G; Lee ATJ; Huang PH; Jones RL
    Eur J Cancer; 2018 Mar; 92():33-39. PubMed ID: 29413687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olaratumab Approved for Soft-Tissue Sarcoma.
    Cancer Discov; 2016 Dec; 6(12):1297. PubMed ID: 27827816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olaratumab: First Global Approval.
    Shirley M
    Drugs; 2017 Jan; 77(1):107-112. PubMed ID: 27995580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olaratumab for soft tissue sarcoma.
    Teyssonneau D; Italiano A
    Expert Opin Biol Ther; 2017 Aug; 17(8):1019-1025. PubMed ID: 28691538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olaratumab for the treatment of soft-tissue sarcoma.
    Pender A; Jones RL
    Future Oncol; 2017 Oct; 13(24):2151-2157. PubMed ID: 28745071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.